's Bulletin Board Post New Topic  Post A Reply
my profile login | register | search | faq | forum home

  next oldest topic   next newest topic
»'s Bulletin Board » .11 and Up! » ***PKTX..ProtoKinetix Files for Patent Protection for AAGP® to be Used in Dry Eye Dis

 - UBBFriend: Email this page to someone!    
Author Topic: ***PKTX..ProtoKinetix Files for Patent Protection for AAGP® to be Used in Dry Eye Dis

Rate Member
Icon 14 posted      Profile for jackbequick     Send New Private Message       Edit/Delete Post   Reply With Quote 
***PKTX..ProtoKinetix Files for Patent Protection for AAGP® to be Used in Dry Eye Disease

Marietta, Ohio, March 19, 2020
ProtoKinetix, Incorporated ( (the "Company" or "ProtoKinetix") (OTCQB:PKTX) recently filed for patent protection for new applications of its AAGP® molecule.

During recent testing conducted by EyeCRO of Oklahoma City, using a well-established animal model for Dry Eye Disease (DED), and Ocular Inflammation it was observed that AAGP® may have a substantial effect on the suppression and control of the disease. Based on these results the company has filed for patent protection with the United States Patent and Trademark Office (USPTO) for the application of DED. The patent application was submitted for both human and veterinary uses.

Dry Eye Disease is one of the most common ocular problems with an estimated prevalence of almost 5-million people over the age of fifty in the United States alone. Current therapies for dry eye are palliative with a focus on the replacement of tears to reduce symptoms. Over-the-counter artificial tear formulations are available. Punctual palliative therapies are also available, and while they have benefits over the short term, they have limited utility in long-term control therapy for dry eye. Cyclosporine A is the first prescription product for dry eye therapy, which increases tear production in patients whose tear production is suppressed. However, Cyclosporine A treatment presents disadvantages over the long term which could potentially be mitigated by AAGP®.

By protecting this technology, the Company is in a better position to move forward with its research in ophthalmological therapies.

“Following the successful completion of recent testing of our AAGP® for dry eye disease, we need to ensure all our intellectual property is patented in order to protect its value.” - said Clarence E. Smith, president and chief executive officer.

Please visit our new website at for more information and to join our email list.

Posts: 193 | From: Florida | Registered: Dec 2009  |  IP: Logged | Report this post to a Moderator

Quick Reply

HTML is enabled.
UBB Code™ is enabled.

Instant Graemlins

Post New Topic  Post A Reply Close Topic   Feature Topic   Move Topic   Delete Topic next oldest topic   next newest topic
 - Printer-friendly view of this topic
Hop To:

Contact Us | Message Board Home

© 1997 - 2021 All rights reserved.

Powered by Infopop Corporation
UBB.classic™ 6.7.2